Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Neo Performance Materials Inc. declares CAD 0.10 dividend (SeekingAlpha) +++ NEO PERFORMANCE Aktie +14,80%

BAVARIAN NORDIC Aktie

 >BAVARIAN NORDIC Aktienkurs 
32.82 EUR    -0.2%    (TradegateBSX)
Ask: 32.9 EUR / 310 Stück
Bid: 32.86 EUR / 310 Stück
Tagesumsatz: 160 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>BAVARIAN NORDIC Performance
1 Woche: -3,1%
1 Monat: +2,8%
3 Monate: +39,4%
6 Monate: +29,3%
1 Jahr: +30,4%
laufendes Jahr: +27,8%
>BAVARIAN NORDIC Aktie
Name:  BAVARIAN NORDIC
Land:  Dänemark
Sektor:  Gesundheit
ISIN/ Wkn:  DK0015998017 / 917165
Symbol/ Ticker:  BV3 (Frankfurt)
Kürzel:  FRA:BV3, ETR:BV3, BV3:GR
Index:  -
Profil:  Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing, and commercialization of vaccines. The company specializes in life-saving immunizations for infectious diseases, with a commercial portfolio that include..
>Volltext..
Marktkapitalisierung:  2626.98 Mio. EUR
Unternehmenswert:  2327.57 Mio. EUR
Umsatz:  855.9 Mio. EUR
EBITDA:  240.1 Mio. EUR
Nettogewinn:  211.04 Mio. EUR
Gewinn je Aktie:  2.74 EUR
Schulden:  17.97 Mio. EUR
Liquide Mittel:  106.25 Mio. EUR
Operativer Cashflow:  196.75 Mio. EUR
Bargeldquote:  2.3
Umsatzwachstum:  -3.53%
Gewinnwachstum:  8.2%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  BAVARIAN NORDIC
Letzte Datenerhebung:  10.11.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 75.99 Mio. St.
Frei handelbar: 84.96%
Rückkaufquote: 1.92%
Mitarbeiter: 1795
Umsatz/Mitarb.: 0.48 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 21.87%
Bewertung:
KGV: 11.93
KGV lG: 16.89
KUV: 2.98
KBV: 1.37
PEG-Ratio: 1.22
EV/EBITDA: 9.69
Rentabilität:
Bruttomarge: 49.2%
Gewinnmarge: 24.66%
Operative Marge: 16.37%
Managementeffizenz:
Gesamtkaprendite: 10.78%
Eigenkaprendite: 12.21%
>Peer Group
Gesundheit, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika, Onkologie/ Krebs- Behandlung
 
06.11.26 - 05:48
Bavarian Nordic secures four-year UK vaccine supply deal (PBR)
 
The deal for the vaccine was awarded through the UK Health Security Agency. Under the contract, the company will deliver scheduled shipments of MVA-BN across the term. The The post Bavarian Nordic secures four-year UK vaccine supply deal appeared first on Pharmaceutical Business review....
02.11.26 - 08:54
Bavarian Nordic – Completion of Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on September 1, 2026, has now been completed, reaching an aggregate amount of approximately DKK 250 million as planned. This represented the first tranche of a total planned share buy-back of up to DKK 750 million. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure through subsequent cancellation of shares repurchased under this program, subject to any necessary additional corporate resolutions, as applicable....
02.11.26 - 08:06
Bavarian Nordic sichert sich britischen Lieferauftrag für Mpox- und Pockenimpfstoff (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.11.26 - 07:31
Bavarian Nordic Awarded Multi-Year Vaccine Contract by UK Government (GlobeNewswire EN)
 
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has been awarded a new multi-year contract by the UK Government through the UK Health Security Agency (UKHSA) for the supply of MVA-BN®, a non-replicating vaccine indicated for the prevention of mpox and smallpox, further supporting the UK's long-term preparedness against emerging infectious disease threats....
27.10.26 - 19:42
Bavarian Nordic to provide over 200K mpox shots to global emergency stockpile (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.10.26 - 19:18
Bavarian Nordic: Großauftrag für Notfallvorrat – Aktie wie entfesselt (Der Aktionaer)
 
Die Aktie des europäischen Impfstoffentwicklers und -herstellers Bavarian Nordic hat am Dienstag ein frisches 52-Wochen-Hoch markiert. Neuigkeiten vom späten Nachmittag könnten dem Wert weitere positive Impulse verleihen....
27.10.26 - 16:54
Bavarian Nordic to Supply and Donate Vaccines for Global Mpox Emergency Stockpile (GlobeNewswire EN)
 
Bavarian Nordic donates 75,000 doses of MVA-BN® and will also supply 150,000 doses to new global mpox vaccine emergency stockpile....
26.10.26 - 10:01
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, October 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
19.10.26 - 11:01
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, October 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
12.10.26 - 17:54
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, October 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
12.10.26 - 10:45
Bavarian Nordic steigt und steigt: Impfstoff-Aktie nicht zu bremsen (Der Aktionaer)
 
Die Aktie des europäischen Impfstoffentwicklers klettert zum Start in die neue Handelswoche auf ein frisches Jahreshoch. Die Erhöhung der Prognose aus der Vorwoche (...
08.10.26 - 09:30
Bavarian Nordic hebt Prognose an – Aktie legt deutlich zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
08.10.26 - 09:09
Bavarian Nordic lifts revenue, margin outlook on U.S. rabies vaccine demand (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
08.10.26 - 08:46
AKTIONÄR-Tipp Bavarian Nordic überrascht schon wieder – Aktie hebt ab (Der Aktionaer)
 
Der europäische Impfstoffentwickler und -hersteller hat am Donnerstag erneut gute Nachrichten für die Aktionäre im Gepäck. Bavarian Nordic wird erneut optimistischer für das laufende Geschäftsjahr. Die Aktie steigt daraufhin auf ein neues Jahreshoch....
08.10.26 - 07:45
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance (GlobeNewswire EN)
 
COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial guidance for the full year 2026, reflecting stronger-than-expected performance in its Travel Health business....
05.10.26 - 08:31
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, October 5, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
28.09.26 - 08:48
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
22.09.26 - 10:01
Bavarian Nordic – Notification of Holding of Treasury Shares (GlobeNewswire EN)
 
COPENHAGEN, Denmark, September 22, 2026 - Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of September 21, 2026, Bavarian Nordic's holding of treasury shares amounted to 3,965,413 shares, corresponding to 5.00% of the Company's share capital and voting rights in the Company. In accordance with Section 85 of the Danish Companies Act, the Company cannot exercise any voting rights attached to its treasury shares....
17.09.26 - 09:54
Führungswechsel bei Bavarian Nordic treibt Aktie an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.09.26 - 09:36
Bavarian Nordic Appoints Former Sanofi Executive as CEO (Bloomberg)
 
Bavarian Nordic A/S appointed former Sanofi executive Tarja Stenvall as its new chief executive officer, resetting leadership after a failed takeover bid led both the chairman and CEO to step down from the vaccine maker....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Schönheit öffnet man jede Türe, vor der Wahrheit schlägt man sie zu. - Lisa Wenger
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!